GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » EV-to-FCF

Valerio Therapeutics (XPAR:ALVIO) EV-to-FCF : -1.03 (As of May. 21, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Valerio Therapeutics's Enterprise Value is €19.30 Mil. Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.78 Mil. Therefore, Valerio Therapeutics's EV-to-FCF for today is -1.03.

The historical rank and industry rank for Valerio Therapeutics's EV-to-FCF or its related term are showing as below:

XPAR:ALVIO' s EV-to-FCF Range Over the Past 10 Years
Min: -26.13   Med: -4.02   Max: -0.57
Current: -1.03

During the past 13 years, the highest EV-to-FCF of Valerio Therapeutics was -0.57. The lowest was -26.13. And the median was -4.02.

XPAR:ALVIO's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs XPAR:ALVIO: -1.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Valerio Therapeutics's stock price is €0.1112. Valerio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.150. Therefore, Valerio Therapeutics's PE Ratio for today is At Loss.


Valerio Therapeutics EV-to-FCF Historical Data

The historical data trend for Valerio Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics EV-to-FCF Chart

Valerio Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.75 -9.13 -3.50 -1.12 -1.47

Valerio Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.50 - -1.12 - -1.47

Competitive Comparison of Valerio Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Valerio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valerio Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's EV-to-FCF falls into.



Valerio Therapeutics EV-to-FCF Calculation

Valerio Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=19.304/-18.78
=-1.03

Valerio Therapeutics's current Enterprise Value is €19.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valerio Therapeutics  (XPAR:ALVIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Valerio Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1112/-0.150
=At Loss

Valerio Therapeutics's share price for today is €0.1112.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Valerio Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Valerio Therapeutics (XPAR:ALVIO) Business Description

Traded in Other Exchanges
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines